Cargando…

TRPM4 and TRPV2 are two novel prognostic biomarkers and promising targeted therapy in UVM

Uveal melanoma (UVM) is the most common primary intraocular malignancy tumor in adults. Almost 50% of UVM patients develop metastatic disease, and is usually fatal within 1 year. However, the mechanism of etiology remains unclear. The lack of prognostic, diagnostic and therapeutic biomarkers is a ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jiong, Qiao, Sen, Liang, Shenzhi, Qian, Cheng, Dong, Yi, Pei, Minghang, Wang, Hongmei, Wan, Guangming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445434/
https://www.ncbi.nlm.nih.gov/pubmed/36081847
http://dx.doi.org/10.3389/fmolb.2022.985434
_version_ 1784783421713678336
author Wang, Jiong
Qiao, Sen
Liang, Shenzhi
Qian, Cheng
Dong, Yi
Pei, Minghang
Wang, Hongmei
Wan, Guangming
author_facet Wang, Jiong
Qiao, Sen
Liang, Shenzhi
Qian, Cheng
Dong, Yi
Pei, Minghang
Wang, Hongmei
Wan, Guangming
author_sort Wang, Jiong
collection PubMed
description Uveal melanoma (UVM) is the most common primary intraocular malignancy tumor in adults. Almost 50% of UVM patients develop metastatic disease, and is usually fatal within 1 year. However, the mechanism of etiology remains unclear. The lack of prognostic, diagnostic and therapeutic biomarkers is a main limitation for clinical diagnosis and treatment. The transient receptor potential (TRP) channels play important roles in the occurrence and development of tumors, which may have the potential as a therapeutic target for UVM. This current study aimed to identify the potential effect and function of the TRPs that could provide survival prediction and new insight into therapy for UVM. Based on the transcriptome data and potential key genes of UVM were screened using the Cancer Genome Atlas (TCGA) databases, Gene expression analysis showed the expression of TRPM4, TRPV2 and other TRPs was high levels in UVM. Using survival analysis, we screened out that the high expression of TRPM4 and TRPV2 was negatively correlated with the prognosis of UVM patients. Cox regression analysis and functional enrichment analysis further indicated that TRPM4 and TRPV2 were the most convincing therapeutic targets of UVM, and the majority of genes involved in ferroptosis pathways in UVM showed positively correlated with the expression levels of TRPM4 and TRPV2. In conclusion, TRPM4 and TRPV2 were considered as two novel prognostic biomarkers and a promising targeted therapy in UVM.
format Online
Article
Text
id pubmed-9445434
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94454342022-09-07 TRPM4 and TRPV2 are two novel prognostic biomarkers and promising targeted therapy in UVM Wang, Jiong Qiao, Sen Liang, Shenzhi Qian, Cheng Dong, Yi Pei, Minghang Wang, Hongmei Wan, Guangming Front Mol Biosci Molecular Biosciences Uveal melanoma (UVM) is the most common primary intraocular malignancy tumor in adults. Almost 50% of UVM patients develop metastatic disease, and is usually fatal within 1 year. However, the mechanism of etiology remains unclear. The lack of prognostic, diagnostic and therapeutic biomarkers is a main limitation for clinical diagnosis and treatment. The transient receptor potential (TRP) channels play important roles in the occurrence and development of tumors, which may have the potential as a therapeutic target for UVM. This current study aimed to identify the potential effect and function of the TRPs that could provide survival prediction and new insight into therapy for UVM. Based on the transcriptome data and potential key genes of UVM were screened using the Cancer Genome Atlas (TCGA) databases, Gene expression analysis showed the expression of TRPM4, TRPV2 and other TRPs was high levels in UVM. Using survival analysis, we screened out that the high expression of TRPM4 and TRPV2 was negatively correlated with the prognosis of UVM patients. Cox regression analysis and functional enrichment analysis further indicated that TRPM4 and TRPV2 were the most convincing therapeutic targets of UVM, and the majority of genes involved in ferroptosis pathways in UVM showed positively correlated with the expression levels of TRPM4 and TRPV2. In conclusion, TRPM4 and TRPV2 were considered as two novel prognostic biomarkers and a promising targeted therapy in UVM. Frontiers Media S.A. 2022-08-23 /pmc/articles/PMC9445434/ /pubmed/36081847 http://dx.doi.org/10.3389/fmolb.2022.985434 Text en Copyright © 2022 Wang, Qiao, Liang, Qian, Dong, Pei, Wang and Wan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Biosciences
Wang, Jiong
Qiao, Sen
Liang, Shenzhi
Qian, Cheng
Dong, Yi
Pei, Minghang
Wang, Hongmei
Wan, Guangming
TRPM4 and TRPV2 are two novel prognostic biomarkers and promising targeted therapy in UVM
title TRPM4 and TRPV2 are two novel prognostic biomarkers and promising targeted therapy in UVM
title_full TRPM4 and TRPV2 are two novel prognostic biomarkers and promising targeted therapy in UVM
title_fullStr TRPM4 and TRPV2 are two novel prognostic biomarkers and promising targeted therapy in UVM
title_full_unstemmed TRPM4 and TRPV2 are two novel prognostic biomarkers and promising targeted therapy in UVM
title_short TRPM4 and TRPV2 are two novel prognostic biomarkers and promising targeted therapy in UVM
title_sort trpm4 and trpv2 are two novel prognostic biomarkers and promising targeted therapy in uvm
topic Molecular Biosciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445434/
https://www.ncbi.nlm.nih.gov/pubmed/36081847
http://dx.doi.org/10.3389/fmolb.2022.985434
work_keys_str_mv AT wangjiong trpm4andtrpv2aretwonovelprognosticbiomarkersandpromisingtargetedtherapyinuvm
AT qiaosen trpm4andtrpv2aretwonovelprognosticbiomarkersandpromisingtargetedtherapyinuvm
AT liangshenzhi trpm4andtrpv2aretwonovelprognosticbiomarkersandpromisingtargetedtherapyinuvm
AT qiancheng trpm4andtrpv2aretwonovelprognosticbiomarkersandpromisingtargetedtherapyinuvm
AT dongyi trpm4andtrpv2aretwonovelprognosticbiomarkersandpromisingtargetedtherapyinuvm
AT peiminghang trpm4andtrpv2aretwonovelprognosticbiomarkersandpromisingtargetedtherapyinuvm
AT wanghongmei trpm4andtrpv2aretwonovelprognosticbiomarkersandpromisingtargetedtherapyinuvm
AT wanguangming trpm4andtrpv2aretwonovelprognosticbiomarkersandpromisingtargetedtherapyinuvm